ArticleBMC cancer2025
ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.Cancer & metabolism · 2026Article
- Cross-cohort integrative multi-omics analysis of cancer essential gene ATP6V0B to dissect functional characteristics and clinical implications in breast cancer.World journal of surgical oncology · 2025Article
- SPP1International journal of genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundATPase H
methodsIn this study, we evaluated the expression of ATP6V0B in BCa and its correlation with patient survival outcomes by performing public database analysis, as well as, RT-qPCR and Western blotting assays. We also investigated the effect of altering the level of expression of ATP6V0B on the malignant behavior of BCa cells at the cellular level by conducting the CCK-8 assay and Transwell assay. In vivo experiments involved subcutaneous injection of stable ATP6V0B-knockdown BCa cells into nude mice to assess the influence of ATP6V0B on tumorigenesis. Additionally, bioinformatics analysis was combined with other methods to predict that ATP6V0B may modulate signaling pathways.
resultsThe findings showed that the expression of ATP6V0B increased in BCa tissues, and patients exhibiting high levels of this protein had a poorer prognosis. Additionally, our results showed that ATP6V0B functions as an oncogene and stimulates the proliferation, invasion, and migration of BCa cells in vitro. In vivo animal studies showed that downregulating ATP6V0B hindered the growth of BCa. Regarding the mechanism of action of ATVP60VB, we found that ATVP60VB can activate the PI3K/AKT signaling pathway through Progestin and AdipoQ Receptor Family Member 4 (PAQR4) -mediated upregulation.
conclusionTo summarize, the results of this study indicated that an increase in the level of expression of ATP6V0B in BCa tissues and cells is associated with unfavorable patient prognosis due to its tumor-promoting effects via upregulation of the PAQR4/PI3K/AKT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.